The growth of prostate cancer is regulated by the androgen receptor (AR), which is a transcription factor that binds with steroid hormones, co-activators and co-receptors of AR, and translocates to the cell nucleus where the AR-complex initiates a number of androgen-related gene transcription events.
Nondioxin-like chemicals assume a noncoplanar configuration with chlorine atoms on the ortho benzene position and bind with variable affinities to steroid hormone receptors.
Because iAs can bind to vicinal thiols which are found in the steroid binding domain and the DNA binding domain of steroid hormone receptors [61], two possible hypotheses are that iAs might inhibit transcription by interfering with either steroid binding to receptor or receptor binding to DNA.
Interestingly, the ancestral vertebrate steroid receptor was a receptor that preferentially bound estrogens, with the progesterone receptor the second steroid receptor to evolve [ 76, 77].
In the third type of mechanism, which is peculiar to steroid hormones and related drugs, the steroid binds to a receptor that consists primarily of nuclear proteins.
Comorbidities were also similar, with the intraoperative steroid use cohort having a higher number of patients with long-term steroid use than the no intraoperative steroid use cohort (6.95% [no steroids] vs. 13.74% [steroid use], P < 0.001).
Secondly, the steroid PS binds to an enantiomer-selective, and thus proteinaceous binding site.
SF-1 binds to shared promoter elements upstream of the steroid hydroxylases to mediate their coordinate expression in steroidogenic cells.
R corresponds to the steroid-hormone receptor, to which the steroid hormone S binds to form a complex RS, which then binds DNA.
First, the steroid molecule may bind in a nonproductive way causing substrate inhibition (91).
